NSW Health logs 1,180 ED visits mentioning unapproved peptides
Retatrutide was named in 833 of the presentations, and monthly counts rose from five in July 2025 to 217 in September 2026.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 19 04:02 ETSource: https://streamlinefeed.co.ke/
The wire
- 01A six-page NSW Health surveillance report published 17 October covers 88 public hospitals and counts 1,180 presentations by patients aged 16 and over where unapproved peptide use was recorded at triage between July 2025 and September 2026.
- 02Eighteen per cent led to admission, with gastrointestinal complaints, chest pain and allergic or medication-related events the commonest primary diagnoses, and 32% of presentations in people aged 25 to 34.
- 03The authors stress the keyword search counts mentions, not unique patients, confirmed exposures or proven harm, and cannot estimate under-counting; product contents, dose and sterility were not verified.
From the source
Read at streamlinefeed.co.keNSW Logs 1,180 Emergency Presentations Mentioning Unapproved Peptides
New South Wales recorded 1,180 emergency-department presentations mentioning unapproved peptide use between July 2025 and September 2026, a state surveillance report says. The monthly count rose from five presentations in July 2025 to 217 in September 2026. The report counts visits where use was noted at triage, not unique people, confirmed product exposures or cases of harm caused by peptides.
